Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors inside the central nervous program, conolidine modulates alternate molecular targets. A Science Innovations review observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By i... https://crosse158fmu2.blue-blogs.com/profile